Sun Pharma Q4 FY26: Profit ₹2,714cr, Dividend ₹5

Results snapshot: profit rises, but QoQ softens

Sun Pharmaceutical Industries Ltd reported a consolidated net profit of ₹2,714 crore for the March 2026 quarter (Q4 FY26), compared with about ₹2,150 crore in the year-ago period. The company also reported a year-on-year rise in revenue from operations for the quarter. While the year-on-year trend remained positive on profit and revenue, the sequential picture was weaker. Profit after tax (PAT) fell 19% quarter-on-quarter from ₹3,369 crore in Q3 FY26. Revenue also declined 6% from ₹15,520 crore reported for the October-December quarter of FY26.

Revenue growth: two reported revenue figures in circulation

In the disclosures and summaries shared around the results, Sun Pharma’s Q4 FY26 revenue was reported in two close figures. One summary stated consolidated revenue of ₹14,612 crore, up from ₹12,959 crore a year earlier. Another stated revenue from operations at ₹14,559.8 crore versus ₹12,815.6 crore in Q4 FY25. Both sets of figures point to low-teens year-on-year growth in the March quarter, even as the company saw a quarter-on-quarter decline from Q3 FY26.

Margin and operating performance: EBITDA at ₹3,954 crore

On operating metrics, Sun Pharma reported EBITDA of ₹3,954 crore for Q4 FY26, a 6.4% year-on-year increase. The EBITDA margin for the quarter stood at 27.1%. These operating numbers provide context to the quarter’s profit performance, especially as the company navigated varying trends across regions. Separately, data cited for the December quarter (Q3 FY26) indicated EBITDA of ₹4,984.4 crore, up 23.4% from ₹4,009 crore a year back, underscoring the sequential step-down into Q4.

India business: formulations grew 14.8%

The company said its India formulations business recorded growth of 14.8% in Q4. It added that the growth was led by the CVD, CNS, Gastro and Ortho segments. This comment signals continued focus on chronic and specialty-heavy therapies within domestic formulations. The statement is also relevant because India remains a core base for Sun Pharma’s branded formulations strategy. The company did not provide additional India sales numbers for Q4 FY26 in the provided text, but it explicitly flagged the therapeutic drivers.

Emerging markets and RoW: growth led by higher revenues

Sun Pharma disclosed that emerging markets revenue stood at $106 million in Q4 FY26, a 17.4% increase over the same period last year. Revenue from Rest of the World (RoW) formulations came in at $120 million, up 10% year-on-year. These numbers show that, alongside India, international markets contributed to the quarter’s year-on-year growth profile. The disclosures provide visibility into regional momentum without detailing profitability by geography.

Specialty contribution: $154 million and 22.2% of revenue

The company also disclosed that sales from a segment rose 20.1% year-on-year to $154 million. This segment accounted for 22.2% of overall revenue during the quarter, as stated in the shared report text. The same context linked performance to “strong growth” in the innovative medicines portfolio and healthy sales across markets. While the text does not break down individual products, it clearly positions specialty and innovation-led revenues as a key driver for the quarter.

Dividend: ₹5 final dividend, FY26 total at ₹16

Alongside the earnings announcement, the board recommended a final dividend of ₹5 per equity share for FY26. This final dividend is subject to shareholder approval at the company’s 34th Annual General Meeting (AGM), as noted in the provided information. The company also stated that this is in addition to an interim dividend of ₹11 per share paid in FY26. That takes the total dividend for FY26 to ₹16 per share, unchanged from FY25.

Key numbers table

Why the quarter matters for investors

The Q4 FY26 print shows a combination of year-on-year profit growth and sequential moderation. The explicit quarter-on-quarter decline in both revenue and PAT highlights that the March quarter did not sustain the December quarter run-rate. At the same time, a 27.1% EBITDA margin and year-on-year growth in EBITDA indicate resilience in operating performance. The dividend recommendation adds a shareholder-return marker that investors typically track alongside earnings.

What to watch next

The final dividend of ₹5 per share will be subject to shareholder approval at the 34th AGM, which is the next formal milestone referenced in the provided information. Investors will also track whether the drivers cited by the company - growth in India formulations and increased contribution from innovation-led and specialty revenues - sustain into subsequent quarters. Further detail on region-wise performance and business mix would typically come through the company’s fuller results presentation and management commentary.